Pharmaceutical R&D
HK inno.N’s GLP-1 Obesity Drug Outperforms Wegovy
Conceptual diagram of the world’s first cyclic adenosine monophosphate (cyclic AMP, cAMP)-biased GLP-1 receptor agonist. By applying a selective signal transduction design (cAMP, right side of image), the drug is said to reduce side effects while enhancing weight loss. Provided by Sciwind Biosciences HK inno.N announced on the 9th that clinical trial results from the United States showed its gluca
2026.06.09